ANIX Anixa Biosciences Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2025Q4*2025-10-31 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 | 2024Q4*2024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.33M | $1.26M | $1.10M | $1.14M | $1.05M | $1.32M | $1.55M | $1.48M |
| SG&A expense | $1.41M | $1.39M | $1.61M | $1.73M | $1.38M | $1.68M | $1.83M | $1.69M |
| Operating income | -$2.74M | -$2.65M | -$2.72M | -$2.88M | -$2.44M | -$3.00M | -$3.39M | -$3.16M |
| Net income | -$2.61M | -$2.52M | -$2.56M | -$2.69M | -$2.26M | -$2.79M | -$3.18M | -$2.88M |
| EPS (basic) | -0.08 | -0.07 | -0.08 | — | -0.07 | -0.09 | -0.10 | — |
| EPS (diluted) | -0.08 | -0.07 | -0.08 | — | -0.07 | -0.09 | -0.10 | — |
| Weighted avg. shares (diluted) | 34.18M | 33.59M | 33.24M | — | 32.48M | 32.20M | 32.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.40M | $1.48M | $1.55M | $1.24M | $1.50M | $1.91M | $1.05M | $1.27M |
| Short-term investments | $12.47M | $12.21M | $12.65M | $13.93M | $14.53M | $13.69M | $16.20M | $18.65M |
| Receivables | — | $56,000 | — | — | — | — | — | $173,000 |
| Current assets | $14.91M | $14.69M | $15.05M | $15.89M | $17.45M | $16.77M | $18.69M | $21.36M |
| Total assets | $15.07M | $14.87M | $15.23M | $16.08M | $17.65M | $16.98M | $18.91M | $21.59M |
| Current liabilities | $1.75M | $1.50M | $1.24M | $1.97M | $2.07M | $1.89M | $2.00M | $2.50M |
| Total liabilities | $1.87M | $1.64M | $1.39M | $2.13M | $2.24M | $2.07M | $2.19M | $2.70M |
| Shareholders' equity | $14.47M | $14.47M | $15.08M | $15.16M | $16.59M | $16.07M | $17.85M | $20.00M |
| Shares outstanding | 34.58M | 33.92M | 33.46M | 33.01M | 32.82M | 32.21M | 32.20M | 32.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.77M | -$1.74M | -$2.61M | -$1.25M | -$1.51M | -$1.50M | -$2.90M | -$927,000 |
| Investing cash flow | -$245,000 | $422,000 | $1.23M | $654,000 | -$833,000 | $2.34M | $2.70M | $867,000 |
| Financing cash flow | $1.94M | $1.25M | $1.69M | $350,000 | $1.93M | $18,000 | -$17,000 | $106,000 |
| Stock-based compensation | $637,000 | $637,000 | $768,000 | $859,000 | $829,000 | $962,000 | $1.03M | $980,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.